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Conclusions. FLD is anobjective tool that asses radiodermatitis. This toolmayproveuseful for the reductionof radiationmorbidities
and improvement of patient quality of life.
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Introduction. Radiation recall dermatitis (RRD) was ﬁrst described by D’Angio in 1959. Its frequency is not known, because most of
the reports are case reports. The interval between the end of RT and RRD ranges from days to years. Anthracyclines, alkylating
agents, antimetabolites, nucleoside analogs, taxanes, tamoxifen, simvastatin, anti-tuberculosis drugs, and exposure to ultraviolet
light, have been associated.
Objective. To assess the frequency and severity of RRD in BCP.
Materials and methods. 350 consecutive BCP undergoing radiotherapy (RT) were enrolled. All patients received supportive skin
treatment before, during and 4 weeks after RT. Follow-up ended 1 year after RT. Dermatitis (D) development during RT was
evaluated by the RTOG/EORTC criteria. RRD was evaluated by the speciﬁc NCI grading system developed in 2000, documented in
the 2.0 Common Toxicity Criteria.
Results. 253 patients presented D during RT. 75 patients had skin toxicity grade II or more. The mean dose of D appearance was
38.8Gy (range 30–42). At 5 months, skin appearance was good in all cases. Later, 19 patients presented RRD (15 GI, and 4 GII). All
these patients had received chemotherapy after RT. All cases improved rapidly with topical steroids.
Conclusions. As far as we know, this is the ﬁrst observational study assessing the frequency and severity of RRD. Idiosyncratic
drug hypersensitivity phenomenon is a recent hypothesis which correlates best with the present available facts. Certain drugs
trigger non-immune inﬂammatory pathways in patients whose inﬂammatory response threshold has been lowered by radiation.
Radiation may induce cells to secrete low levels of cytokines, such as TNF, that are responsible for an inﬂammatory response,
and when a triggering agent is introduced, these cytokines are upregulated, causing a recall reaction. Often, the recall reaction
is more severe than the original radiation reaction, which has not occurred in the patients we studied. Study continues.
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Introduction. In radiation-induced-cancer development are implicated low range radiation doses (up to 20–30Gy) received by the
healthy tissue, except for secondary sarcoma induced at higher doses.
Objective. To analyze the effects of 10–16Gy boost given [as second cancers potential-inducer in homolateral (HL) and contralateral
lung (CL) and breast (CB)], and ascertain if there is any difference if delivered by photons (PH) or electrons (E). We present the
preliminary results.
Materials and methods. 5 consecutive BCP, treated with conservative intend, undergoing RT, were enrolled. Eclipse v10.0 was used
for planning and DVH analysis. Statistical analysis was performed by MATLAB software. For each patient, two boost options were
calculated; one by PH and another by E. DVH of each were analyzed and determined: (a) V5-20Gy of HL and CL. (b) V5-10Gy of
CB. (c) V10-20Gy of esophagus. Also, the mean integral dose in the treated breast (MIDB) and the mean integral dose received in
the whole simulation volume (MIDWSV) were determined.
Results. Wilcoxon–Mann–Whitney test showed that the null hypothesis was true (median equal for both data samples, with a
signiﬁcance level of 5%) for HL, but false for MIDB and MIDWSV. Therefore, no signiﬁcant differences were found in HL between
both boost (PH or E), but they were found for MIDB (increased for E) and for MIDWSV (increased for PH).
Conclusions. There is a signiﬁcant difference between E or PH boost regarding low doses in distant organs. No differences were
found regarding lung doses. E boost possibly is more related to higher probability of homolateral induced breast sarcoma. Integral
dose (linked to general cancer induction) is also higher in PH boost. This low dose distribution might be used as optimization
criteria for a certain patient regarding election between E or PH boost with similar CTV coverage.
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